No significant effect,as compared with placebo, was observed withregard to the primary end point in the 50-mg group (hazard ratio, 0.93; P = 0.30) (Fig. 2A). Bycontrast, a significant effect for the primary endpoint was observed in the 150-mg group (hazardratio vs. placebo, 0.85; P = 0.02075, with a thresh-old P value of 0.02115) (Fig. 2B)